AFM
YTEN

Anson Funds Management’s Yield10 Bioscience, Inc. Common Stock YTEN Stock Holding History

Anson Funds Management’s Portfolio YTEN Stock Details YTEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-163
Closed -$277K – 58
2017
Q4 		$277K Buy
+163
New +$441K 0.19% 50

Other funds holding YTEN

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Anson Funds Management's YTEN Position: Q1 2018 in Review

Anson Funds Management sold out of Yield10 Bioscience, Inc. Common Stock (YTEN) in Q1 2018, closing a stake of 163 shares — an estimated $277K sold.

Anson Funds Management first reported a position in YTEN in Q4 2017 and held it in 1 quarter. The position peaked at $277K in Q4 2017. 10 funds tracked by Wall St. Rank hold YTEN as of Q1 2018.

  • Anson Funds Management reported no remaining Yield10 Bioscience, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Anson Funds Management sold 163 Yield10 Bioscience, Inc. Common Stock shares in Q1 2018, an estimated $277K.
  • Anson Funds Management first reported a position in Yield10 Bioscience, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Anson Funds Management's Yield10 Bioscience, Inc. Common Stock position peaked at $277K in Q4 2017.
  • 10 funds tracked by Wall St. Rank held Yield10 Bioscience, Inc. Common Stock as of Q1 2018.

Based on Anson Funds Management's 13F filing for Q1 2018, filed 15 May 2018.